Table 1.

Summary of study characteristics (n = 5)

Reference	Trial numbers	Setting	Study region	Upper urinary tract carcinoma included	Neoadjuvant pretreatment allowed	Radiation pretreatment allowed	Drug	Sample size; % female	Survival end point for gender analysis	Follow-up period	Quality of life data included	Special features
Aragaki et al. (2022)	IMvigor 210, 406 patients from TCGA MIBC	Phase II, metastatic and advanced disease, multi-centric	North America	Yes	No	Yes	Atezolizumab	406; 26.4 (for TCGA data)	OS	No detailed information in publication	No	Detailed analysis for gender-specific biomarkers
Bajorin et al. (2021)	CheckMate 275	Phase III, adjuvant for advanced and high-risk, multi-centric	North and South America, Europe, Asia, Australia	Yes	Yes	No	Nivolumab	709; 23.8 (analysis with 353 with 24.9% females)	DFS; RFS and recurrence rates	Median 20.9 months	Yes	–
Bellmunt et al. (2017)	Keynote-045	Phase III, metastatic and advanced, second-line, multi-centric	North America, Europe	Yes	Yes	No	Pembrolizumab	542; 25.8	OS; death rates	Median 14.1 months	No	–
Bellmunt et al. (2021)	IMvigor 010	Phase III, adjuvant for advanced and high-risk, multi-centric	North America	Yes	Yes	No	Atezolizumab	809; 21.1 (analysis with 406 with 20.7% females)	Median DFS disease rates	Median 21.9 months	No	–
Hoffman-Censits et al. (2019) [Abstract]	PCD4989g, IMvigor 210, IMvigor 211, SAUL	Pooled Analysis, locally advanced and metastatic disease, multi-centric	Worldwide	Yes	Yes	No	Atezolizumab	1995; 22.6 pooled analysis for: A) PCD4989g: 95; 24.2 B) IMvigor 211 atezo: 467; 23.6	Median OS, ORR; disease rates	Different among included studies	No	–